

www.nrpj.in | www.nrpj.com

JOURNAL OF NEUROSCIENCES IN RURAL PRACTICE

The Official Journal of the International Journal of the
Association of Rural Universities Neurosciences (IJNRU)

Editor in Chief
Dr. Anil Kumar



Scientific Scholar®
International Journal

Publication of International Journals

JOURNAL OF NEUROSCIENCES IN RURAL PRACTICE

The Official Journal of the
Asociación Ayuda Enfermo Neuroquirúrgico (AAEN)



 ScientificScholar®

Search here..



Editorial Board

Last updated on: February 9, 2023

The editorial board comprises of a panel of experts from various disciplines of medical and allied sciences to provide their expertise and guidance in maintaining the clarity of content and focus of the purpose for the journal.

Editor-in-Chief

Amit Agrawal

Department of Neurosurgery,
All India Institute of Medical Sciences,
Saket Nagar, Bhopal,
Madhya Pradesh, India

Email: editor@ruralneuropractice.com;
dramitagrawal@gmail.com

Executive Editors

(Review)

Arvind Bhake

Department of Pathology,
Jawaharlal Nehru Medical College,
Sawangi, Maharashtra, India

Email: aravani@rediffmail.com

(Office)

Jake Timothy

Department of Neurosurgery, Institute,
Leeds General Infirmary,
Leeds, United Kingdom

Email: jaketimothy@mac.com

Editorial Advisor

Sagar Galwankar

Department of Emergency Medicine,
University of Florida, Jacksonville,
Florida, United States

Email: gcsagar@yahoo.com

Associate Editors

Dhaval P. Shukla

Professor & HOD of Neurosurgery
2nd Floor (Right Wing),
Neurosciences Faculty Center,
NIMHANS, Dr. MH Marigowda Road,
Bangalore 560029, India.

Email: dhavalshukla@nimhans.ac.in

Board Editors

Ajay Singh

College of Education and Technology
Eastern New Mexico University
1500 S Ave K Portales, NM 88130 USA
Email: ajaysingh363@gmail.com

Andres M. Rubiano

Neurosciences & Neurosurgery,
Neurosciences Institute, Universidad El Bosque,
Bogotá, Colombia
Email: andresrubiano@aol.com

Angelos Kolias

Division of Neurosurgery,
University of Cambridge & Addenbrooke's Hospital,
Cambridge, United Kingdom
Email: angeloskolias@gmail.com

Anupam Gupta

Department of Neurological Rehabilitation,
National Institute of Mental Health & Neuro Sciences,
Bengaluru, Karnataka, India
Email: drgupta159@yahoo.co.in

Dr. Awadhesh Kumar Jaiswal

Department of Neurosurgery,
Sanjay Gandhi Postgraduate Institute of Medical Sciences,
Rae Bareilly Road,
Lucknow (UP) INDIA-226014
Email: akjaiswal@saggi.ac.in

Aki Hietaharju

Department of Neurology and Rehabilitation, Tampere University Hospital & Adjunct Professor of
Neurology, Faculty of Medical and Life Sciences, University of Tampere, Tampere, Finland
Email: hietahar@kolumbus.fi

Arthur Robert Kurzbuch

Department of Pediatric Neurosurgery,
Alder Hey Children's Hospital
NHS Foundation Trust,
Liverpool, United Kingdom
Email: kurzbuch@web.de

Azmi Alias

Department of Neurosurgery, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia
Email: azmidr@hotmail.com

Daniel Agustin Godoy

Critical Care Department,
Hospital de Agudos, San Juan Bautista, Sanatorio Pasteur,
Catamarca, Argentina
Email: dagodoytorres@yahoo.com.ar

Dwarakanath Srinivas

Department of Neurosurgery, National Institute of Mental Health and Neurosciences,
Bengaluru, Karnataka, India
Email: dwarakaneuro@yahoo.com

Fazlul Hoque

Square Hospital Ltd,
18/F, Bir Uttam Qazi Nuruzzaman Sarak, West Panthapath
Dhaka 1205 Bangladesh
Email: fazlul@squarehospital.com

Knut Wester

Section for Neurosurgery, Department of Surgical Sciences, University of Bergen, 5021, Bergen, Norway

Email knutwester@hotmail.com

Lateef Thanni

Department of Surgery,
Olabisi Onanjo University / Teaching Hospital,
Sagamu, Ogun State, Nigeria
Email: loathanni@yahoo.com

Luis Rafael Moscote-Salazar

International Consortium of Neurological Research
USA
Email: rafaelmoscote21@gmail.com

Manish Vaish

Max Super Speciality Hospital,
New Delhi, India
Email: vaman2172@yahoo.co.in

Manish Ranjan

Department of Neurosurgery,
Rockefeller Neuroscience Institute, West Virginia University,
Morgantown, WV, United States
Email: drmanishranjan@gmail.com

Mehmet Turgut

Department of Neurosurgery,
Aydin Adnan Menderes University,
Efeler, Aydin, Turkey
Email: drmturgut@yahoo.com

Mehmet Zileli

Department of Neurosurgery,
Ege University,
Izmir, Turkey
Email: zilelim@gmail.com

Mohamed Mohi Eldin

Head of Minimally Invasive Spine Unit
Department of Neurosurgery,
Faculty of Medicine,
Cairo University,
Cairo, Egypt
Email: mmohi63@yahoo.com

Dr. Mohan R. Sharma

Professor and Head,
Department of Neurosurgery,
Tribhuvan University Teaching Hospital
Director of Research,
Institute of Medicine Kathmandu, Nepal
Email: mohanrajsharma@gmail.com

Pablo Peleato Gistau

Chief of Service Traumatology and Orthopaedics. Barbastro Hospital (Spain) Carretera Nacional 240,
s/n, 22300 Barbastro, Huesca
Email: pablopeleato@hotmail.com

Pankaj K. Upadhyay

Department of Neurosurgery,
Institute of Human Behaviour and Allied Sciences,
New Delhi, India
Email: upadhyaypk5@yahoo.co.in

Rabi Narayan Sahu

Department of Neurosurgery,
All India Institute of Medical Sciences,
Bhubaneswar, Odisha, India
Email: drnsahu@gmail.com

Ramez Wadie Kirollos

Department Neurosurgery,
National Neuroscience Institute,
Singapore

Email: kirollos77@hotmail.com

Ranabir Pal

Professor and Head, Department of Community Medicine
ESIC Medical College and Hospital, Faridabad- 121001, NCR Delhi, India

Email: ranabirmon@yahoo.co.in

Riaz Raja Memon

Department of Neurosurgery,
Liaquat University of Medical & Health Sciences,
Jamshoro, Pakistan

Email: riazrajamemon@yahoo.com

Soumitra Das

Department of Psychiatry,
NWMH,
Melbourne, Australia

Email: soumitratdmc@gmail.com

Srinivas Kosagi

Department of Psychiatry,
Dharwad Institute of Mental Health and Neurosciences,
Dharwad, Karnataka, India

Email: kosgi1974@gmail.com

Tariq Janjua

Department of Critical Care Medicine, Physicians Regional Medical Center, Naples, FL, USA

Email: Tariq.M.Janjua@HealthPartners.Com

Vijay P. Joshi

Department of Neurosurgery, Yashodhara Superspeciality Hospital, CNS Hospital, Sparsh Neurocare,
Solapur, Maharashtra, India

Email: vpjjoshi@rediffmail.com

Virendra Deo Sinha

Head of Department
Department of neurosurgery
Santokba Durlabhji Memorial Hospital cum Medical Research Institute,
Jaipur, India


Email: sinhavd59@gmail.com

Yaroslav Winter

Head of Mainz Comprehensive Epilepsy Center, Senior consultant, Medical Center of Johannes
Gutenberg-University, Mainz, Germany

mail: yaroslav.winter@unimedizin-mainz.de

Search here..





The Effect of ACTH(4–10) PRO8-GLY9-PRO10 Administration on the Expression of IL-6 and IL-8 in Sprague Dawley Mice with Spinal Cord Injury

Muhammad Azzam¹ Achmad Fahmi¹ Budi Utomo² Muhammad Faris¹
Muhammad Arifin Parenrengi¹ I. Ketut Sudiana³ Abdul Hafid Bajamal¹ Eko Agus Subagio¹

¹ Department of Neurosurgery, Faculty of Medicine, Universitas Airlangga, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia

² Department of Public Health-Preventive Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

³ Department of Pathological Anatomy, Faculty of Medicine, Universitas Airlangga, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia

Address for correspondence Eko Agus Subagio, MD, PhD, Department of Neurosurgery, Faculty of Medicine, Universitas Airlangga, Dr. Soetomo General Academic Hospital, Jalan Mayjend Prof. Dr. Moestopo No. 6-8, Mojo, Gubeng, Surabaya, East Java, 60285, Indonesia (e-mail: eko.agus@fk.unair.ac.id).

J Neurosci Rural Pract

Abstract

Background Spinal cord injury (SCI) is a significant cause of morbidity since it results in the inflammation process which leads to necrosis or apoptosis. Inflammatory response to the tissue damage increases IL-6 and IL-8 levels. ACTH4–10Pro8-Gly9-Pro10 is a peptide community that has been shown to have a beneficial effect on minimizing the morbidity and increasing the recovery time.

Methods This study is a true experimental laboratory research with a totally randomized method. The subjects were animal models with light and extreme compression of spinal cord, respectively.

Results The administration of *ACTH 4–10* in mild SCI in the 3-hour observation group did not show a significant difference in *IL-6* expression compared with the 6-hour observation group. The administration of *ACTH 4–10* in severe SCI showed a significantly lower expression level of *IL-6* in the 3-hour observation group compared with the 6-hour one. The administration of *ACTH 4–10* in severe SCI led to a significantly lower *IL-8* expression in the 3-hour observation group compared with the 6-hour one. However, there was no significant difference in *IL-8* expression in the group receiving *ACTH 4–10* in 3 hours observation compared with that in 6 hours observation.

Conclusion The administration of ACTH4–10Pro8-Gly9-Pro10 can reduce the expression of IL-6 and IL-8 at 3-hour and 6-hour observation after mild and severe SCI in animal models. Future research works are recommended.

Keywords

- ▶ ACTH4–10Pro8-Gly9-Pro10
- ▶ spinal cord injury
- ▶ IL-6
- ▶ IL-8

DOI <https://doi.org/10.1055/s-0042-1744468>.
ISSN 0976-3147.

© 2022. Association for Helping Neurosurgical Sick People. All rights reserved.

This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (<https://creativecommons.org/licenses/by-nc-nd/4.0/>)

Thieme Medical and Scientific Publishers Pvt. Ltd., A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

Introduction

Spinal cord injury (SCI) carries a physical and mental burden as it causes permanent motoric and sensory dysfunctions and significantly lowers the quality of life. It causes neurological deficits through primary injury, due to irreversible, direct, and mechanical damage to the myelin during the impact, and secondary injury mechanisms.¹ From the previous study, it is known that 24 hours after trauma is the golden period to conduct a decompression surgery, and yet there has not been any strict guideline for the benefit of the surgery conducted in the acute or later phase of SCI.^{2,3} There is a controversial therapy for SCI, which includes the administration of high-dose methylprednisolone that could give more side effects instead of therapeutical effects.⁴ In the future, the treatment approach to SCI will involve blocking the inflammation and progressive pathogenesis of SCI, stimulating the regeneration of neurons.

Inflammation in SCI could induce the apoptosis cascade that leads to cell death. The role of inflammation in SCI's pathophysiology suggested us to test *ACTH(4-10) Pro8-Gly9-Pro10*, a neuromodulator agent that could trigger an anti-apoptosis effect. We conducted an experiment in SCI-induced *Sprague Dawley* mice and administered them with intranasal *ACTH(4-10) Pro8-Gly9-Pro10*, and later, we collected the myelin to identify *IL-6* and *IL-8* through immunohistochemistry staining.⁶ This study aimed to discover more ways to treat inflammation from SCI with the possibility for its future clinical application in increasing the recovery rate and decreasing the morbidity rate.

Materials and Methods

This study is a true experimental laboratory study with a completely randomized design. It was conducted in the Animal Laboratorium Universitas Airlangga and Pathology Anatomy and Biochemistry Department in the Faculty of Medicine Universitas Brawijaya over the course of 3 months period.

The subjects were divided into the control group which did not receive any compression to the spinal cord, while sham and treatment groups received spinal cord compression on the T2 level. The control and treatment groups were divided into 20 and 35 g compression groups for mild and severe compression simulation, respectively. The sham group received a placebo using normal saline, while the treatment group received *ACTH 4-10* 300 µg/kg (P) through intranasal drops. Spinal cord transection was done for sham and treatment groups after 3 and 6 hours on the level of injury. The tissues were observed by deparaffinization and immunohistochemistry staining of *IL-6* and *IL-8*, and the levels of *IL-6* and *IL-8* were measured under a light microscope with 400x magnification of all areas.

The data were collected in a controlled environment with the same treatment. The levels of *IL-6* dan *IL-8* were presented in a relative expression graph. The normality of the data was tested with the Shapiro-Wilk test. Normally distributed data were analyzed using the analysis of variance followed by post hoc analysis using the Tukey method.

Results

IL-6 Expression in Mild SCI

► **Table 1** shows post hoc test results of *IL-6* expression in mild SCI with the Tukey HSD method ($p < 0.05$).

Mild SCI with the administration of NaCl 0.9% in 3-hours and 6-hour observation groups and with the administration of *ACTH 4-10* in the 3-hour observation group showed a significantly higher mean of *IL-6* expression compared with controls. However, the administration of *ACTH 4-10* in mild SCI in the 3-hour observation group did not show a significant difference compared with that in the 6-hour observation group.

IL-6 Expression in Severe SCI

► **Table 2** shows post hoc test results of *IL-6* expression in severe SCI with the Tukey HSD method ($p < 0.05$).

Table 1 Post hoc test results of *IL-6* expression in mild SCI with the Tukey HSD method ($p < 0.05$)

Group	Mean	Standard deviation	Group	Mean	Standard deviation	<i>p</i> -Value
Control	3.00	1.63	3 h SCI	10.43	3.05	0.001 ^a
			6 h SCI	13.43	3.60	0.001 ^a
			3 h SCI + <i>ACTH 4-10</i>	8.43	2.51	0.005 ^a
			6 h SCI + <i>ACTH 4-10</i>	10.71	1.89	0.001 ^a
3 h SCI	10.43	3.05	6 h SCI	13.43	3.60	0.235
			3 h SCI + <i>ACTH 4-10</i>	8.43	2.51	0.621
			6 h SCI + <i>ACTH 4-10</i>	10.71	1.89	1.000
6 h SCI	13.43	3.60	3 h SCI + <i>ACTH 4-10</i>	8.43	2.51	0.011 ^a
			6 h SCI + <i>ACTH 4-10</i>	10.71	1.89	0.326
3 h SCI + <i>ACTH 4-10</i>	8.43	2.51	6 h SCI + <i>ACTH 4-10</i>	10.71	1.89	0.496

Abbreviation: SCI, spinal cord injury.

^aSignificant at p -value < 0.05 .

Table 2 Post hoc test results of IL-6 expression in severe SCI with the Tukey HSD method ($p < 0.05$)

Group	Mean	Standard deviation	Group	Mean	Standard deviation	p-Value
Control	2.86	1.07	3 h SCI	18.71	2.75	0.001 ^a
			6 h SCI	27.71	1.70	0.001 ^a
			3 h SCI + ACTH 4-10	10.71	1.38	0.001 ^a
			6 h SCI + ACTH 4-10	16.00	2.31	0.001 ^a
3 h SCI	18.71	2.75	6 h SCI	27.71	1.70	0.001 ^a
			3 h SCI + ACTH 4-10	10.71	1.38	0.001 ^a
			6 h SCI + ACTH 4-10	16.00	2.31	0.093
6 h SCI	27.71	1.70	3 h SCI + ACTH 4-10	10.71	1.38	0.001 ^a
			6 h SCI + ACTH 4-10	16.00	2.31	0.001 ^a
3 h SCI + ACTH 4-10	10.71	1.38	6 h SCI + ACTH 4-10	16.00	2.31	0.001 ^a

Abbreviation: SCI, spinal cord injury.

^aSignificant at p -value < 0.05 .

IL-6 expression in severe SCI with the administration of ACTH 4-10 in 3- and 6-hour observation groups showed a significantly lower mean compared with the administration of NaCl 0.9%. The administration of ACTH 4-10 in severe SCI showed a significantly lower expression level of IL-6 in the 3-hour observation group compared with the 6-hour observation group.

IL-8 Expression in Mild SCI

Table 3 shows post hoc test results of IL-8 expression in mild SCI with the Tukey HSD method ($p < 0.05$).

There was a significant difference ($p < 0.05$) in all comparisons, excluding the IL-8 expression in severe SCI with the administration of NaCl 0.9% in the 3-hour observation group compared with the administration of ACTH 4-10 in the 6-hour observation group. IL-8 expression in severe SCI with the administration of ACTH 4-10 in 3- and 6-hour observation groups showed a significantly lower mean compared with the administration of NaCl 0.9% in 3- and 6-hour

observation groups. The administration of ACTH 4-10 in severe SCI led to a significantly lower IL-8 expression in the 3-hour observation group compared with the 6-hour one.

IL-8 Expression in Severe SCI

Table 4 showed post hoc test results of IL-8 expression in severe SCI with the Tukey HSD method ($p < 0.05$).

In severe SCI, the administration of ACTH 4-10 showed a significantly lower IL-8 expression level compared with the administration of NaCl 0.9% either in 3- or 6-hour observation groups. There was no significant difference in IL-8 expression in the group receiving ACTH 4-10 in 3-hour observation compared with that in 6 hours.

Discussion

Spinal injury could lead to assorted injuries, including SCI. The clinical manifestation of SCI could vary from spinal cord

Table 3 Post hoc test results of IL-8 expression in mild SCI with the Tukey HSD method ($p < 0.05$)

Group	Mean	Standard deviation	Group	Mean	Standard deviation	p-Value
Control	3.43	0.98	3 h SCI	12.86	1.86	0.001 ^a
			6 h SCI	18.57	1.90	0.001 ^a
			3 h SCI + ACTH 4-10	7.57	2.07	0.001 ^a
			6 h SCI + ACTH 4-10	12.14	1.68	0.001 ^a
3 h SCI	12.86	1.86	6 h SCI	18.57	1.90	0.001 ^a
			3 h SCI + ACTH 4-10	7.57	2.07	0.001 ^a
			6 h SCI + ACTH 4-10	12.14	1.68	0.938
6 h SCI	18.57	1.90	3 h SCI + ACTH 4-10	7.57	2.07	0.001 ^a
			6 h SCI + ACTH 4-10	12.14	1.68	0.001 ^a
3 h SCI + ACTH 4-10	7.57	2.07	6 h SCI + ACTH 4-10	12.14	1.68	0.001 ^a

Abbreviation: SCI, spinal cord injury.

^aSignificant at p -value < 0.05 .

Table 4 Post hoc test results of *IL-8* expression in severe SCI with the Tukey HSD method ($p < 0.05$).

Group	Mean	Standard Deviation	Group	Mean	Standard Deviation	<i>p</i> -Value
Control	3.43	1.99	3 h SCI	28.71	6.42	0.001 ^a
			6 h SCI	30.14	4.14	0.001 ^a
			3 h SCI + <i>ACTH</i> 4–10	11.00	2.65	0.009 ^a
			6 h SCI + <i>ACTH</i> 4–10	14.57	2.64	0.001 ^a
3 h SCI	28.71	6.42	6 h SCI	30.14	4.14	0.958
			3 h SCI + <i>ACTH</i> 4–10	11.00	2.65	0.001 ^a
			6 h SCI + <i>ACTH</i> 4–10	14.57	2.64	0.001 ^a
6 h SCI	30.14	4.14	3 h SCI + <i>ACTH</i> 4–10	11.00	2.65	0.001 ^a
			6 h SCI + <i>ACTH</i> 4–10	14.57	2.64	0.001 ^a
3 h SCI + <i>ACTH</i> 4–10	11.00	2.65	6 h SCI + <i>ACTH</i> 4–10	14.57	2.64	0.443

Abbreviation: SCI, spinal cord injury.

^aSignificant at p -value < 0.05 .

commotion, contusion, laceration, hemorrhage, compression, to transection. SCI is divided into two processes involving a mechanical primary injury and secondary injury. The process of injury leads to inflammation and apoptosis.⁷ Programed cell death leads to demyelination and axonal degeneration of the injury. Most of cell deaths that were studied resulted from primary injury and then continues to secondary injury. These two mechanisms are mediated by several types of inflammation, free radicals inducing cell deaths, and glutamate excitotoxicity.⁵ Cytokines pathway modulates the central nervous system's inflammation by stimulating the other inflammatory cytokines, chemokines, nitric oxide, and reactive oxygen species.⁸ Cytokines in leukocytes pathway that causes cell death are also the ones we studied here, which are *IL-6* and *IL-8*.

Vascular damage by SCI harms the blood–brain barrier (BBB) after which the injury's location is quickly infiltrated by neutrophils. This process of vascular damage mainly contributes to the progression of secondary injury, which the primary injury happens in the first 3–24 hours after SCI. *IL-6* and *TNF- α* are the first pro-inflammatory cytokines released in the first 30 to 45 of the injuries. Around the injured tissue, the production of *IL-6* and *TNF- α* is abundantly significant.⁹ *TNF- α* modulates the apoptosis of spinal cord neurons in mice through glutamate pathway, and it was reported that the administration of *TNF* antagonists decreases the development of inflammation and tissue damage caused by SCI.¹⁰

The increase of *IL-1* cytokine family, like *IL-1 α* , was reported as clear evidence of an important role it plays in inducing inflammation caused by SCI.^{7,11,12} Central nervous system gives a response to the inflammation in SCI initiated by immune cells from peripheral tissue and activates glial cells that proliferate and migrate to the injury site after SCI.⁹ T cells play an essential role in activating macrophages and modulating the cellular immune response. Macrophages and microglial cells contribute to the pathogenesis of secondary injury and cytokine release in inflammation, *TNF- α* , *IL-1*, *IL-6*, *IL-8* dan *IL-10*.⁷ Thus, *TNF- α* and *IL-1* play an important role in

apoptosis caused by SCI and it is mediated by a cytokine pathway.

Surgical treatment in SCI is aimed to increase the quality of life, whereas the prevention of secondary treatment is aimed to at least avoid further damage that could lead to a permanent and long-term disability that could deteriorate the patient's quality of life. The administration of *ACTH(4–10) Pro8-Gly9-Pro10* by blocking the *M2 receptor* is expected to decrease the apoptosis in SCI, so it could be considered as a therapy regimen in addition to indicated surgical treatment. The administration of *ACTH(4–10) Pro8-Gly9-Pro10* is done by intranasal drops. It works by diffusion through the olfactory tract's perineural cavity and trigeminal nerve branch, retrograde axonal transport, nose capillary micro-circulation, until it reaches the central nervous system. In 1 to 4 minutes, it arrives at the BBB and cerebrospinal fluid, and the effect lasts from 20 to 24 hours even after the compound has already been eliminated.¹³ It is known that secondary lesion happens in 24 hours after the primary lesion so the treatment is given as early as less than 24 hours after the primary lesion.

***IL-6* Expression in Acute Spinal Cord Compression Injury**

Based on the results of this study, in a mild SCI group administered with *ACTH(4–10) Pro8-Gly9-Pro10*, a statistically significant difference was observed in 3 hours administration compared with 6 hours in the expression of *IL-6*, both in mild and severe SCI. This shows that the administration time of *ACTH(4–10) Pro8-Gly9-Pro10* has a great impact on the expression of inflammatory cytokines. It can be concluded that early administration of *ACTH(4–10) Pro8-Gly9-Pro10* in both mild and severe SCI is expected to modulate inflammation leading to the decrease of secondary lesion of neurons and glial cells from the injury. It is also concluded that in SCI, the early administration, less than 3 hours, is expected to help modulate pro-inflammatory cytokines because of the significant gap of *IL-6* expression compared with the control group.

This finding is suitable with the existing theories and previous studies that the administration of *ACTH(4-10) Pro8-Gly9-Pro10* as an anti-inflammation drug prevents secondary lesion by repairing neurons, blocking the *M2 receptor* activity, and decreasing the level of anti-inflammatory cytokines.⁷ A previous study showed a drastic increase of *IL-6* expression and its receptor during an acute phase of SCI. This is linked with the function of *IL-6* that could induce the differentiation of neural stem cell into astrocyte that leads to scar formation (glial scar).¹⁴ Another experiment conducted the suppression of *IL-6* where in vitro study shows the suppression of astrocytic differentiation, whereas in vivo study shows the inhibition of astrogliosis. The depletion of *IL-6* in SCI-induced animals also shows the decrease of inflammatory cells in the injury site and the decrease of scar formation severity and results in a better neurological repair in SCI-induced mice.¹⁴

IL-8 Expression in Acute Spinal Cord Compression Injury

Trauma in spinal cord leads to increase in the level of *IL-8* that functions as a chemoattractant that induces the migration of inflammatory cells like neutrophils to the inflammation site.¹⁵ *IL-8* is produced by macrophage and somatic cell that regulate neutrophil and T cell. *IL-8* has a peak level in the first 24 hours in SCI. This is caused by the activation of microglial and neutrophils infiltrating the parenchyma cells.⁷

Based on the results of this study, in mild SCI group administered with *ACTH(4-10) Pro8-Gly9-Pro10*, a statistically significant difference was observed in 3 hours administration compared with 6 hours in the expression of *IL-8* both in mild and severe SCI, showing that the administration time of *ACTH(4-10) Pro8-Gly9-Pro10* also plays a major role in the inflammatory cytokines expression.

This finding is linked to the discovery saying that glucocorticoids play a role in blocking *IL-8*. The level of cortisol is inversely proportional to *IL-8* and other cytokines. Therefore, it is concluded that ACTH could indirectly decrease the level of *IL-8* through cortisol pathway.¹⁶

Conclusion

The administration of *ACTH 4-10* could decrease the expression of one or more *IL-6* and *IL-8* in SCI model animals with spinal cord compression, both in mild and severe SCI and at 3 hours and 6 hours. The decrease of *IL-6* and *IL-8* mostly in a severe compression of the spinal cord as its level increased on a higher level compared with the mild compression. *ACTH 4-10* might be a viable option to be studied further specifically for SCI in reducing glial formation and irreversible inflammatory damage. Further experiments are needed for analyzing the mechanism of the action of *ACTH 4-10* in inhibiting inflammation in SCI.

Ethical Approval

This study has not involved human subjects.

Funding

None.

Conflict of Interest

None declared.

Acknowledgment

The completion of this paper could not have been possible without the support and assistance of seniors of the Faculty of Medicine, Universitas Airlangga, and many others whose names cannot be mentioned one by one.

References

- Okada S. The pathophysiological role of acute inflammation after spinal cord injury. *Inflamm Regen* 2016;36(01):20
- Fehlings MG, Perrin RG. The timing of surgical intervention in the treatment of spinal cord injury: a systematic review of recent clinical evidence. *Spine* 2006;31(11, Suppl):S28-S35, discussion S36
- Batchelor PE, Wills TE, Skeers P, et al. Meta-analysis of pre-clinical studies of early decompression in acute spinal cord injury: a battle of time and pressure. *PLoS One* 2013;8(08):e72659
- Varma AK, Das A, Wallace G IV, et al. Spinal cord injury: a review of current therapy, future treatments, and basic science frontiers. *Neurochem Res* 2013;38(05):895-905
- Stammers AT, Liu J, Kwon BK. Expression of inflammatory cytokines following acute spinal cord injury in a rodent model. *J Neurosci Res* 2012;90(04):782-790
- Poon PC, Gupta D, Shoichet MS, Tator CH. Clip compression model is useful for thoracic spinal cord injuries: histologic and functional correlates. *Spine* 2007;32(25):2853-2859
- Kwon BK, Stammers AMT, Belanger LM, et al. Cerebrospinal fluid inflammatory cytokines and biomarkers of injury severity in acute human spinal cord injury. *J Neurotrauma* 2010;27(04):669-682
- Gensel JC, Zhang B. Macrophage activation and its role in repair and pathology after spinal cord injury. *Brain Res* 2015;1619:1-11
- Donnelly DJ, Popovich PG. Inflammation and its role in neuroprotection, axonal regeneration and functional recovery after spinal cord injury. *Exp Neurol* 2008;209(02):378-388
- Fleming JC, Norenberg MD, Ramsay DA, et al. The cellular inflammatory response in human spinal cords after injury. *Brain* 2006;129(Pt 12):3249-3269
- Ni H, Jin W, Yuan B, et al. Curcumin inhibits the increase of labile zinc and the expression of inflammatory cytokines after traumatic spinal cord injury in rats. *J Surg Res* 2014;187(02):646-652
- Yang L, Jones NR, Blumbergs PC, et al. Severity-dependent expression of pro-inflammatory cytokines in traumatic spinal cord injury in the rat. *J Clin Neurosci* 2005;12(03):276-284
- Ahuja CS, Wilson JR, Nori S, et al. Traumatic spinal cord injury. *Nat Rev Dis Primers* 2017;3(01):17018
- Nakamura M, Okada S, Toyama Y, Okano H. Role of *IL-6* in spinal cord injury in a mouse model. *Clin Rev Allergy Immunol* 2005;28(03):197-204
- Kang J, Jiang MH, Min HJ, et al. IKK- β -mediated myeloid cell activation exacerbates inflammation and inhibits recovery after spinal cord injury. *Eur J Immunol* 2011;41(05):1266-1277
- Schuld C, Franz S, Brüggemann K, et al; EMSCI study group. International standards for neurological classification of spinal cord injury: impact of the revised worksheet (revision 02/13) on classification performance. *J Spinal Cord Med* 2016;39(05):504-512